OptimizeRx Corporation Q3 2025 Earnings Recap
Published November 7, 2025
OptimizeRx reported a robust Q3 2025 with revenues of $26.1 million, reflecting a 22% year-over-year growth, and an adjusted EBITDA of $5.1 million, exceeding expectations.
The numbers
Reported results against what analysts expected.
Earnings per share
$0.20
vs $0.03 expected · beat by 566.7%
Revenue
26067000
vs 30914570 expected · missed by 15.7%
Nov 7 to Nov 14
-3.0%
the days after
Nov 7 to Dec 10
-11.37%
the weeks after
Key takeaways
From the Q3 2025 earnings call.
- Revenue guidance for FY 2025 has been raised to $105-$109 million, with adjusted EBITDA now expected between $16-$19 million.
- Average revenue from the top 5 customers has grown beyond $11 million, demonstrating strong client relationships and engagement.
- The company continues to reduce its debt, paying down an additional $2 million, and does not anticipate needing to access equity capital markets in the near future.
- Gross margin improved to 67.2%, driven by a favorable product and channel mix, alongside disciplined cost management efforts.
- Initial guidance for FY 2026 indicates revenue of $118-$124 million and adjusted EBITDA of $19-$22 million, signaling confidence in future growth.
Your portfolio
Track earnings for the stocks you own
Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.
Also published on November 7, 2025
This summary was written by AI from the official earnings call transcript. It is for information only and is not financial advice. For OPRX's price history and fundamentals, see the OPRX stock page.